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Panton-Valentine Leukocidin (PVL) is a staphylo-
coccal bicomponent pore-forming toxin linked to
severe invasive infections. Target-cell and species
specificity of PVL are poorly understood, and the
mechanism of action of this toxin in Staphylococcus
aureus virulence is controversial. Here, we identify
the human complement receptors C5aR and C5L2
as host targets of PVL, mediating both toxin binding
and cytotoxicity. Expression and interspecies varia-
tions of the C5aR determine cell and species speci-
ficity of PVL. The C5aR binding PVL component,
LukS-PV, is a potent inhibitor of C5a-induced
immune cell activation. These findings provide
insight into leukocidin function and staphylococcal
virulence and offer directions for future investiga-
tions into individual susceptibility to severe staphylo-
coccal disease.
INTRODUCTION
In the early 1930s, Panton and Valentine described a powerful
leukocidal toxin produced by multiple Staphylococcus aureus
isolates. This leukocidin, now known as Panton-Valentine leuko-
cidin (PVL), is cytotoxic to neutrophils and, to a lesser extent, to
monocytes and macrophages, but not to lymphocytes (Gaudu-
chon et al., 2001; Meyer et al., 2009; Panton and Valentine,
1932). PVL is a prophage-encoded, bicomponent, pore-forming
exotoxin comprising the protein subunits LukS-PV and LukF-PV
(Diep et al., 2006; Panton and Valentine, 1932). Initial binding of
LukS-PV to the surface of target cells, which is an essential step,
triggers secondary binding of LukF-PV (Colin et al., 1994). This
subsequently induces the assembly of lytic pore-forming
hetero-octamers (Jayasinghe and Bayley, 2005). At sublytic
concentrations, PVL enhances host responses by priming of
susceptible cells (Graves et al., 2012; Yoong and Pier, 2012).
The in vitro susceptibility of neutrophils to PVL differs consider-
ably among mammalian species (Hongo et al., 2009; Lo¨ffler584 Cell Host & Microbe 13, 584–594, May 15, 2013 ª2013 Elsevier Iet al., 2010; Olsen et al., 2010). While human and rabbit neutro-
phils are highly susceptible,murine andmacaque neutrophils are
resistant to PVL. Themolecular basis for the selectivity of PVL for
certain cell types and species is not understood, although the
involvement of a myeloid-specific receptor has been suggested
(Gauduchon et al., 2001).
S. aureuscauses variousdiseases ranging fromsuperficial skin
andsoft tissue infections (SSTI) to severe invasivedisease (DeLeo
et al., 2010). In the 1990s, methicillin-resistant S. aureus (MRSA)
was found to infect previously healthy individuals. Since then,
community-associated (CA) MRSA strains have rapidly emerged
worldwide (Vandenesch et al., 2003). The majority of CA-MRSA
isolates carry prophages with the genes encoding PVL, partially
due to the successful spread of the PVL-carrying clone USA300
in the United States (DeLeo et al., 2010; Vandenesch et al.,
2003). Based on epidemiological studies, noticeably those con-
ducted in countries with a low prevalence of CA-MRSA, PVL is
associated with skin and soft tissue infections (Shallcross et al.,
2013) and severe necrotizing pneumonia in otherwise healthy in-
dividuals (Gillet et al., 2002; Hidron et al., 2009; Lina et al., 1999).
However, the role of PVL is still under debate, partly due to the
difficulty of addressing this issue in experimental mice models
of disease (Bubeck Wardenburg et al., 2007; Labandeira-Rey
et al., 2007; Voyich et al., 2006). In rabbit models of necrotizing
pneumonia, PVL was recently confirmed to contribute to the
severity of disease (Diep et al., 2010).
Species specificity is a common characteristic of other
immune modulators secreted by staphylococci. This selectivity
can often be reduced to high-affinity protein-protein interactions,
depending on unique amino acid sequences of host targets
(Rooijakkers et al., 2005). The chemotaxis inhibitory protein of
S. aureus (CHIPS) targets the extracellular N terminus of the
human C5a receptor (C5aR, CD88), a seven-transmembrane
G protein-coupled receptor (GPCR) (Postma et al., 2005). C5a,
a powerful anaphylatoxin, is released during complement activa-
tion. Detection of invading bacteria by phagocytes via the C5aR
is considered one of the earliest innate recognition events
(Woodruff et al., 2011). By inhibiting the human C5aR,
CHIPS efficiently blocks neutrophil activation and recruitment
in vitro (de Haas et al., 2004). C5a is a ligand for another
seven-transmembrane receptor known as C5L2 (GPR77).nc.
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Although closely related to the C5aR, C5L2 is not coupled to a
G protein and therefore has no direct intracellular signaling activ-
ity (Monk et al., 2007).
Here, we report the identification of the human C5a receptors,
C5aR and C5L2, as receptors for LukS-PV and mediators of
PVL-induced cytotoxicity. We illustrate that expression and
interspecies variations of the C5a receptors drive cell and spe-
cies specificity of PVL toxicity.
RESULTS
LukS-PV Binds the Human C5aR and C5L2
Figure 1A confirms that LukS-PV binds to human neutrophils and
monocytes but not to lymphocytes (Colin et al., 1994; Gaudu-
chon et al., 2001; Jayasinghe and Bayley, 2005), suggesting
the involvement of a specific receptor. LukF-PV alone does not
bind to any of the cell populations (Colin et al., 1994). Both com-
ponents of PVL were tested for interference with the binding of
monoclonal antibodies directed toward 56 different receptors
on leukocytes as described earlier (Bardoel et al., 2012). Incuba-
tion of neutrophils and monocytes with LukS-PV specifically
decreased the binding of three antibodies recognizing different
epitopes of the human C5aR (Figure 1B), suggesting an interac-
tion between LukS-PV and this receptor. As expected, LukF-PV
alone did not inhibit the binding of any of the monoclonal anti-
bodies. No interference was observed for binding of antibodies
directed toward other receptors, as illustrated by the antibody
for an unrelated GPCR, CXCR2 (Figure 1B). Binding of LukS-PV
to neutrophils was inhibited by the ligand of the C5aR, C5a, and
by the staphylococcal C5aR antagonist CHIPS (de Haas et al.,
2004) (Figure 1C), further indicating an interaction between
LukS-PV and the C5a receptor.
To confirm the interaction between LukS-PV and theC5aR, we
tested LukS-PV binding to U937 promyelocytic cells stably
transfected with the human C5aR. LukS-PV specifically bound
to cells transfected with the human C5aR, but not to nontrans-
fected cells or cells stably transfected with CXCR2 (Figure 1D).
Since C5a is the ligand for the C5aR and the closely related
receptor C5L2, LukS-PV binding to human embryonic kidney
(HEK) cells stably transfected with the C5L2 was investigated.
Indeed, LukS-PV bound to C5L2 transfected cells (Figure 1D).
The half-maximal effective binding concentration of LukS-PV
was calculated to be 6.2 nM (SD ±5.1) for the C5aR-transfected
cells, 15.2 nM (SD ±6.2) for the C5L2-transfected cells, and
2.8 nM (SD ±1.2) for human neutrophils, without statistically
significant differences (Figure 1E).
As LukS-PV binding is mediated by both C5a receptors, we
evaluated relative receptor expression levels of the C5aR and
C5L2 on leukocyte populations freshly isolated from different
donors. Both receptors were present on neutrophils and mono-
cytes but not detectable on lymphocytes (Figure 1F). In agree-
ment with previous studies (Gao et al., 2005; Woodruff et al.,
2011), we found that the ratio of C5aR to C5L2 was 68 on neutro-
phils (SD ±18.1, p < 0.001) and 33 on monocytes (SD ±13.1,
p < 0.01). Thus, of both receptors, the C5aR will be most readily
available for LukS-PV. Relative receptor expression levels of the
C5aR on transfected cells used in this study were comparable to
neutrophils. The C5L2 on the transfected cells was expressed inCell Hrelatively high amounts compared to neutrophils (Figure S1A
available online). The low level of C5L2 expression on neutrophils
indicates that binding of LukS-PV to neutrophils is mainly driven
by the C5aR.
Since the TLR2/CD14 receptor complex was recently reported
to be involved in PVL-induced lung inflammation in mice (Ziv-
kovic et al., 2011), we tested binding of LukS-PV to HEK cells
cotransfected with the human TLR2 and CD14. However, no
binding was observed (Figure S1B).
These data collectively demonstrate that LukS-PV binds both
the human C5a receptors C5aR and C5L2. Binding of LukS-PV
to neutrophils is mainly driven by the C5aR.
PVL-Induced Pore Formation Is Mediated by the Human
C5aR and C5L2
To evaluate whether binding of LukS-PV to the C5aR and C5L2
mediates cytotoxicity of target cells, we tested induction of cell
permeability using a membrane-impermeant fluorescent dye.
Only cells transfected with the C5aR or C5L2 were susceptible
to PVL-induced pore formation, while nontransfected cells or
cells transfected with the CXCR2 were fully resistant (Figures
2A and 2B). We confirmed C5a-receptor-mediated cytotoxicity
of PVL using crude bacterial supernatants of wild-type
S. aureus USA300-LAC, a common CA-MRSA isolate in the
United States, and its isogenic PVL mutant (luks/f-pv knockout)
strain (Voyich et al., 2006). Pore formation was observed when
supernatant of the wild-type bacterium was applied to C5aR-
and C5L2-transfected cells. No lysis was induced by culture
supernatant of the PVL-negative mutant strain (Figure 2C). Since
PMA-differentiated THP-1 macrophages are sensitive to PVL-
induced pore formation, we used small hairpin RNA (shRNA)-
mediated silencing of C5aR expression to study the effect on
PVL cytotoxicity. Silencing C5aR expression led to a strong
decrease in LukS-PV binding and a concomitant reduction of
PVL-induced pore formation in THP-1 macrophages (Figure 2D).
In line with the negative binding experiments of TLR2/CD14-
cotransfected cells, no pore formation was detected when PVL
was applied to these cells (Figure S1C).
If the C5aR is the major PVL receptor, C5aR competition
should interfere with toxicity. Indeed, pretreatment of human
neutrophils with C5a or CHIPS shifted the half-maximal effective
lytic concentration of PVL from 0.9 nM (SD ±0.2) for untreated
cells to 3.1 nM (SD ±0.6) for C5a-treated cells (p < 0.001) and
3.5 nM (SD ±1.0) for CHIPS-treated cells (p < 0.001). The staph-
ylococcal protein FLIPr-like, binding two unrelated GPCRs
expressed on neutrophils (Prat et al., 2009), did not influence
susceptibility of the cells (Figure 2E). However, because high
concentrations of CHIPS were needed to antagonize PVL-
induced pore formation (Figure S2A), we studied the expression
of both CHIPS and PVL in the culture supernatant of S. aureus
USA300-LAC (Figures S2B and S2C). In different broths, CHIPS
was produced in insufficient amounts to compete with PVL for
interaction with the C5aR (Figures S2C and S2D). The induction
of pore formation by various PVL-carrying clinical S. aureus iso-
lates was similar, irrespective of the presence of the gene encod-
ing CHIPS (Figure S2E). Antagonism of PVL by CHIPS under
physiological circumstances therefore seems unlikely.
Taken together, these data demonstrate that PVL uses
both the C5aR and C5L2 to induce pore formation. Sinceost & Microbe 13, 584–594, May 15, 2013 ª2013 Elsevier Inc. 585
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Figure 1. LukS-PV Binds the Human C5aR and C5L2
(A) LukS-PV (12 nM) binds human neutrophils and monocytes but not lymphocytes.
(B) Binding inhibition of different antibodies directed toward the human C5aR and CXCR2 by LukS-PV or LukF-PV (protein subunit concentrations, 313 nM).
(C) Binding competition of LukS-PV (60 nM) by C5a or CHIPS (600 nM) on neutrophils.
(D) LukS-PV (31 nM) binding to U937 and HEK cells.
(E) Concentration-dependent binding of LukS-PV to neutrophils and transfected cells, expressed in relation to maximal binding at 31 nM. The dashed line
indicates 50% of maximal fluorescence.
(F) Receptor expression levels on neutrophils as compared to isotype control, quantified by calibration to defined antibody binding capacity units. The dashed line
indicates the detection threshold. Bars represent SD, with n = 3. Statistical significance is displayed as *p < 0.05, **p < 0.01, or ***p < 0.001 using two-way ANOVA
with Bonferroni posttest correction for multiple comparison. Histograms depict a representative example. See also Figure S1.
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Figure 2. PVL-Induced Pore Formation Is Mediated by the Human C5aR and C5L2
(A and B) Pore formation in transfected U937 (A) and HEK (B) cells using different concentrations of PVL.
(C) PVL in bacterial supernatant induces C5aR- and C5L2-mediated lysis. Pore formation induced by 5% overnight CCY-based bacterial supernatant applied to
transfected U937 and HEK cells.
(D) Binding of LukS-PV (LukS-PV concentration 31 nM, line) to and pore formation (PVL concentration 2.8 nM, columns) in PMA-differentiated THP-1 cells
expressing different c5ar1-targeting shRNA, with relative C5aR mRNA expression levels as determined by quantitative RT-PCR. Binding of LukS-PV expressed
as maximal binding to cells transduced with an empty construct.
(E) Pore formation inhibition in neutrophils by C5a (100 nM), CHIPS (710 nM), or FLIPr-like (833 nM). The dashed line indicates 50% permeable cells. Permeable
cells are PI or DAPI positive. Bars express SD, with n = 3. Statistical significance is displayed as **p < 0.01 using Student’s t test. See also Figure S2.
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C5aR can protect human neutrophils against PVL-induced
pore formation.Cell HPVL-Induced Priming Is Mediated by the Human C5aR
Since sublytic concentrations of PVL were recently reported to
prime neutrophil responses (Graves et al., 2012; Yoong andost & Microbe 13, 584–594, May 15, 2013 ª2013 Elsevier Inc. 587
AB
Figure 3. PVL-Induced Priming of Neutrophils Is Mediated by the
Human C5aR
(A and B) Priming was antagonized by pretreatment of cells with 700 nM of the
specific C5aR antagonist CHIPS31–121. Shown in (A): oxidative burst of neu-
trophils induced by 1 mM fMLP after priming with 10 ng/ml TNF-a, 1 nM C5a,
and 0.25 to 1 nM PVL. Oxidative burst, detected by luminescence, is
expressed as relative area under the curve (AUC). Shown in (B) is a repre-
sentative example of C5aR-dependent priming by PVL. The oxidative burst is
expressed as relative light units (RLU) induced by an injection of 1 uM fMLP
(arrow) after priming cells with 1 nM PVL. Bars express SD, with n = 2–6.
Statistical significance is displayed as *p < 0.05 using Student’s t test.
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Figure 4. PVL Shows Species Specificity for Both Binding to and
Pore Formation In Neutrophils
(A and B) LukS-PV binding to (A) and PVL-induced pore formation in (B) freshly
isolated human, mouse, macaque, and rabbit neutrophils. Permeable cells are
PI or DAPI positive. Bars express SD, with n = 2. Histograms depict a repre-
sentative example. See also Figure S3.
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are mediated by the C5aR as well. Indeed, C5a, tumor necrosis
factor a (TNF-a), and low concentrations of PVL increased
the N-formyl-methionine-leucine-phenylalanine (fMLP)-induced
oxidative burst by neutrophils. Priming by C5a and PVL, but
not by TNF-a, was fully antagonized after preincubation of cells
with the specific C5aR antagonist CHIPS31–121 (Haas et al., 2005)
(Figures 3A and 3B). This shows that priming induced by sublytic
concentrations of PVL is mediated by the C5aR.
The C5aR Determines Species Specificity of PVL
Murine and macaque neutrophils do not bind LukS-PV and are
resistant to PVL-induced pore formation, while human and rabbit
neutrophils bind LukS-PV and are fully susceptible to PVL cyto-
toxicity (Figure 4) (Hongo et al., 2009; Lo¨ffler et al., 2010; Olsen
et al., 2010). All species tested showed expression of the C5aR588 Cell Host & Microbe 13, 584–594, May 15, 2013 ª2013 Elsevier Ion the surface of neutrophils (Figure S3). Therefore, species
specificity of PVL could not be explained simply by the presence
or absence of the C5aR. Because of significant interspecies vari-
ation within the amino acid sequences of the C5aR, we tested
whether binding of LukS-PV to the C5aR could explain the pre-
viously observed species specificity of PVL (Hongo et al.,
2009; Lo¨ffler et al., 2010; Olsen et al., 2010). Cells transfected
with the murine or macaque C5aR showed no binding of LukS-
PV (Figure 5A) and were fully resistant to PVL-induced pore for-
mation (Figure 5B). However, cells expressing the rabbit C5aR
bound LukS-PV comparable to the human C5aR and were highly
susceptible to PVL-mediated pore formation. As murine and
macaque neutrophils are intrinsically resistant to PVL (Lo¨ffler
et al., 2010), the interaction of PVL with the C5L2 of both mam-
mals was not further studied. In summary, these experiments
show that interspecies variations of the C5aR determine species
specificity of PVL.
The C5aR Core Region Is Critical for PVL-Induced Pore
Formation
To evaluate which regions of the C5a receptors are targeted by
PVL, we tested different receptor constructs in HEK cells for their
ability to mediate LukS-PV binding and PVL-induced pore for-
mation (Figures 6A and 6B). Cells transfected with the extracel-
lular N termini of C5aR or C5L2 showed only weak binding of
LukS-PV at high concentration. Moreover, binding to these
N termini was insufficient to cause pore formation. This observa-
tion was confirmed by experiments with cells expressing a
chimeric receptor composed of the C3a receptor (C3aR) corenc.
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Figure 5. The C5aR Determines Species Specificity of PVL
(A) LukS-PV binding to HEK cells transfected with the human, mouse,
macaque, and rabbit C5aR.
(B) PVL-induced pore formation in transfected HEK cells. Permeable cells are
DAPI positive. Bars express SD, with n = 2–3. Histograms depict a repre-
sentative example. See also Figure S4.
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PV to this chimera was exclusively observed at high concentra-
tion, and cells were resistant to PVL-induced pore formation.
Transfected cells expressing the opposite chimera of the C5aR
core domain and the C3aR extracellular N terminus showed
similar binding but were partially susceptible to pore formation.
These data show that LukS-PV binds both N terminus and
core regions of the C5aR, while the latter of these two is critical
for PVL to induce pore formation.
Since LukS-PV binds the N terminus of the C5aR, interaction
of LukS-PV with the N terminus was further investigated in solid
phase. Binding of LukS-PV to the N terminus was weaker as
compared to CHIPS (Figure 6C) and dependent on sulphation
of the receptor on residues 11 and 14 (Figure 6D). Sulphation
of these residues is crucial for CHIPS to bind as well (de Haas
et al., 2004). Using isothermal titration calorimetry, a KD of
127 nM (SD ±17 nM) was calculated for LukS-PV to bind the
C5aR N terminus (Figure 6E). This KD is approximately 10-fold
higher than that of CHIPS (de Haas et al., 2004).
Altogether, these findings indicate a complex interaction
between LukS-PV and the C5aR as a whole but demonstrate
that cytotoxic activity of PVL is highly dependent on the core
regions of the C5aR.
LukS-PV Is a Potent Inhibitor of the Human C5aR
Activation of the C5aR by C5a results in a transient rise of intra-
cellular calcium concentrations. When applied alone, LukS-PV
and LukF-PV are not cytotoxic (Colin et al., 1994). As LukS-PV
targets the C5aR, we tested if LukS-PV acts as a functional inhib-
itor of cellular activation by detection of intracellular calciumCell Hmobilization. LukS-PV, but not LukF-PV, strongly antagonized
activation induced by C5a on both human neutrophils (Figure 7A)
and U937 cells transfected with the C5aR (Figure 7B). Inhibition
was independent of the N terminus of the C5aR, since LukS-PV
also antagonized activation induced by the C-terminal C5a pep-
tide Tyr65, Phe67 65–74 (Figure 7C). This peptide only interacts
with the core region of the C5aR (Chen et al., 1998). In contrast,
CHIPS binds the extracellular N terminus of the C5aR and there-
fore can only inhibit full-length C5a (de Haas et al., 2004). Collec-
tively, these data identify LukS-PV as an inhibitor of the human
C5aR, which is at least as potent as CHIPS. These experiments
further reveal a complex interplay between the protein and the
receptor, confirming an interaction of LukS-PV with the core
region of the C5aR.
DISCUSSION
We show that LukS-PV binds the human C5a receptors C5aR
and C5L2. As a functional bicomponent toxin, PVL uses the
C5a receptors to induce pore formation in the target cell mem-
brane. Receptor expression profiles of the C5a receptors on
different cell populations explain 80-year-old observations in
which PVL was reported to target neutrophils, monocytes, and
macrophages, but not lymphocytes, since the latter are negative
for expression of both C5aR and C5L2 (Gao et al., 2005; Gaudu-
chon et al., 2001; Gerard and Gerard, 1991; Meyer et al., 2009;
Monk et al., 2007; Panton and Valentine, 1932; Woodruff et al.,
2011). The number of LukS-PV receptors estimated in a more
recent study matches the combined expression level of both
C5a receptors on neutrophils (Gauduchon et al., 2001). Although
some nonmyeloid cells express both C5a receptors, expression
levels are low compared to myeloid cells (Haviland et al., 1995).
The abundant expression, notably on neutrophils, makes the
C5aR a readily available target for the toxin and allows the toxin
to distinguish phagocytic cells from other cells. In our experi-
mental setup, the protection of human neutrophils against
PVL-induced pore formation by the specific C5aR inhibitor
CHIPS indicates that the C5aR is the major receptor for PVL
on neutrophils, and C5L2 the minor receptor. Decreased sus-
ceptibility of C5aR-silenced THP-1 macrophages for PVL cyto-
toxicity supports the notion that the C5aR is the major PVL
receptor and further indicates that the existence of anothermajor
PVL receptor is highly unlikely.
In a recent report, TLR2 and CD14 were presented as an
essential receptor complex for PVL-induced lung inflammation
in mice (Zivkovic et al., 2011). However, in another publication,
antibodies specific for TLR2, TLR4, and CD14 failed to inhibit
PVL-mediated priming of human neutrophils for enhanced func-
tion (Graves et al., 2012). We have shown that HEK cells stably
transfected with the human TLR2/CD14 do not bind LukS-PV
and are resistant to PVL-induced pore formation. Although we
cannot exclude secondary effects mediated by the TLR2/CD14
receptor complex, it is clearly not involved in direct cytotoxicity
of PVL since mice as well as mouse neutrophils are intrinsically
resistant (Hongo et al., 2009; Lo¨ffler et al., 2010).
Our findings show that the immune-activating properties
of PVL at sublytic concentrations, as observed by others
(Graves et al., 2012; Yoong and Pier, 2012), are mediated by
the human C5aR as well. Using in vitro infection experiments,ost & Microbe 13, 584–594, May 15, 2013 ª2013 Elsevier Inc. 589
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Figure 6. The C5aR Core Region Is Critical
for PVL-Mediated Lysis
(A) LukS-PV binding to HEK cells transfected with
the N termini of the C5aR or C5L2 or chimera
receptors composed of the C5aR and C3aR.
(B) PVL-induced pore formation (PVL concentra-
tion, 625 nM) in transfected HEK cells.
(C and D) Binding of LukS-PV to the solid-phase
C5aR N terminus on an ELISA plate (C) is depen-
dent on sulphation of residues Y11 and Y14
(100 nM LukS-PV) (D).
(E) Isothermal titration calorimetry plot showing the
association of the C5aR N terminus with LukS-PV.
Permeable cells are DAPI positive. Bars express
SD, with n = 3–4. Statistical significance is
displayed as **p < 0.01 or ***p < 0.001 using Stu-
dent’s t test. Histograms depict a representative
example. See also Figure S5.
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by S. aureus could not be obtained (data not shown). As shown
by others, direct killing of neutrophils byS. aureus is independent
of PVL (Ventura et al., 2010).
LukS-PV binds to both the N-terminal and core domain of the
human C5aR. However, binding of LukS-PV to the host cell in
itself is not sufficient to trigger pore formation. A specific interac-
tion with the core domain, likely resulting from conformational
changes, is required for cytotoxic activity. Because of the limited
sequence homology of only 35% between the C5aR and C5L2,
prediction of relevant amino acids is difficult (Monk et al.,
2007). Most probably, major determinants will be present in
the three extracellular domains. This hypothesis is supported
by our observations that LukS-PV antagonizes stimulation with
a C-terminal C5a peptide (Tyr65, Phe67 65–74), which only inter-
acts with the core region of the C5aR (Chen et al., 1998). The
affinity of LukS-PV for the C5aR as a whole, therefore, is pre-
dicted to be considerably higher than the one we calculated
for the N-terminal C5aR alone. Next to being part of a590 Cell Host & Microbe 13, 584–594, May 15, 2013 ª2013 Elsevier Inc.two-component pore-forming toxin, we
identified LukS-PV as a potent inhibitor
of the human C5aR by antagonizing
C5a-induced activation of neutrophils.
This indicates that, next to CHIPS,
S. aureus produces another molecule to
interact with the C5aR (de Haas et al.,
2004). When applied alone, LukS-PV
and LukF-PV are not cytotoxic (Colin
et al., 1994). Due to its genetic arrange-
ment in an operon structure, secretion of
LukS-PV by the pathogen is accompa-
nied by the other protein subunit, LukF-
PV (Colin et al., 1994; Diep et al., 2006),
allowing formation of the cytotoxin on
the target cell. Although LukS-PV antago-
nizes C5a-induced activation of neutro-
phils in vitro, it remains unclear if func-
tional inhibition of the C5aR by LukS-PV
alone contributes to pathogenesis of
S. aureus. Since CHIPS is expressed atinsufficient amounts by CHIPS-PVL coproducing S. aureus
strains, antagonism of PVL-induced pore formation by CHIPS
seems unlikely under physiological circumstances. Insight into
the interaction of LukS-PV with the C5a receptors will be of value
for the development of anti-inflammatory drugs in C5a-mediated
diseases (Woodruff et al., 2011).
Recently, the staphylococcal leukocidin combination LukED
was reported to target the human immunodeficiency virus core-
ceptor CCR5, which like the C5aR is a member of the GPCR
family (Alonzo et al., 2013). Although not fully explaining the
cell selectivity of LukED, the interaction of LukED with CCR5
highlights the relevance of CCR5-positive leukocytes in the path-
ogenesis of S. aureus. Together with the identification of the
C5aR and C5L2 as the PVL receptors presented here, the report
on LukED and CCR5 suggests an apparent common interac-
tion of staphylococcal bicomponent pore-forming toxins with
GPCRs.
PVL is an example of bacterial toxins and modulators, espe-
cially of staphylococcal origin, exhibiting pronounced species
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Figure 7. LukS-PV Inhibits the C5a-Induced Cell Activation
(A–C) Calcium mobilization with 1 nM C5a (A and B) in human neutrophils (A)
and U937-C5aR cells (B) or 2.5 mM C-terminal C5a (C) in U937-C5aR cells
inhibited by increasing concentrations of LukS-PV and CHIPS. Bars express
SD, with n = 3.
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Haas et al., 2004; Prat et al., 2009; Rooijakkers et al., 2005). Over
the last few years, many studies have been published address-
ing the contribution of PVL to virulence of S. aureus in animal
models of infection. Confusing reports on experiments in mice
have provoked an intense international debate both for SSTI
and necrotizing pneumonia (Bubeck Wardenburg et al., 2007;
Labandeira-Rey et al., 2007; Voyich et al., 2006). With our proof
of C5aR-mediated interspecies susceptibility for PVL-induced
cytotoxicity, animal studies addressing the role of PVL in patho-
genesis of S. aureus can now be better interpreted. We have
demonstrated that cells transfected with the mouse and even
macaque C5aR are fully resistant, while cells transfected with
the rabbit C5aR are susceptible to PVL-induced pore formation.
This is in line with previously described species-specific suscep-
tibility of primary cells in vitro (Hongo et al., 2009; Lo¨ffler et al.,
2010). Our data showing clear C5aR-mediated interspecies sus-
ceptibility for PVL-induced cytotoxicity offer a molecular expla-
nation for the observed stronger relevance of rabbit versus
mice models to study PVL-associated pathogenesis. Although
the contribution of PVL to skin infections in rabbits is still under
debate (Kobayashi et al., 2011; Lipinska et al., 2011), experi-
ments by others in rabbits confirm PVL as a phagocyte-targeting
virulence factor in S. aureus necrotizing pneumonia (Diep et al.,
2010). Unfortunately, the staphylococcal C5aR antagonist
CHIPS does not bind the rabbit C5aR (de Haas et al., 2004)
and a monoclonal anti-human C5aR antibody does not protect
against PVL-induced pore formation in rabbit neutrophils (data
not shown), limiting us to investigate the contribution to staphy-
lococcal pathophysiology of the interaction between PVL and
the C5aR of a compatible species. It remains to be elucidatedCell Hif lung epithelial cells are damaged indirectly by PVL-affected
neutrophils and macrophages (Niemann et al., 2012; Perret
et al., 2012) or directly via low expression of the C5aR (Haviland
et al., 1995).
The underlying mechanisms for the predisposition of other-
wise healthy human individuals to infrequent but highly lethal
necrotizing pneumonia are poorly understood. Although often
preceded by influenza-like symptoms contributing to suscepti-
bility (Gillet et al., 2002; Hidron et al., 2009), human genetic fac-
tors might account for a poor outcome (Alcaı¨s et al., 2009). Vari-
ation in the expression of the C5a receptors is a likely candidate
to explore for genetic determinism in PVL-associated disease.
EXPERIMENTAL PROCEDURES
Recombinant Protein Production and Purification
Polyhistidine-tagged LukS-PV and LukF-PV, CHIPS, CHIPS31–121, and FLIPr-
like were cloned and expressed as described elsewhere (de Haas et al., 2004;
Haas et al., 2005; Perret et al., 2012; Prat et al., 2009). The S. aureus strains
used as template are shown in Table S1.
Bacterial Strains and Culture
LAC is a USA300 pulsotype CA-MRSA isolate. LACDpvl, its isogenic PVL
knockout strain, was donated by Frank R. DeLeo (Rocky Mountain Labora-
tories, Hamilton, MT, USA) (Voyich et al., 2006). All strains were cultured in
casein hydrolysate and yeast extract (CCY) medium (optimal expression of
leukocidins) (Lipinska et al., 2011;Woodin, 1959), tryptic soy broth, or Iscove’s
modified Dulbecco’s medium (IMDM). Overnight supernatants were sterilized
by a 0.2 mm filter and stored at 20C. Experiments with clinical S. aureus
isolates and quantification of CHIPS and PVL expression are described in Sup-
plemental Experimental Procedures.
Cell Isolation, Cell Lines, and Transfections
Human leukocytes, obtained from healthy volunteers, and macaque (Macaca
fascicularis) and rabbit (New Zealand white) leukocytes were isolated by Ficoll/
Histopaque centrifugation (de Haas et al., 2004). Murine leukocytes (BALB/c)
were derived from bone marrow. U937 cells (a human promyelocytic cell line)
stably transfected with the C5aR, CXCR2, or an empty expression vector were
obtained from Eric R. Prossnitz (University of New Mexico, Albuquerque, NM,
USA) (Kew et al., 1997). HEK293T cells (a human embryonic kidney cell line)
stably transfected with the C5L2 were donated by Peter N. Monk (Sheffield
University Medical School, Sheffield, UK) (Kalant et al., 2003). HEK293T cells
coexpressing TLR2 and CD14 were obtained from InvivoGen.
HEK293T cells were transfected according to the manufacturer’s protocols
with 4 mgDNA and 5 ml Lipofectamine 2000 (Invitrogen) for full-length receptors
or with 2 mg DNA and 13 ml Polyethylenimine MAX (PolySciences) for N-termi-
nal receptors. After 24–48 hr, transfected cells were harvested with 0.05%
trypsin/0.53 mM EDTA. Cells transiently transfected with the full-length recep-
tors were labeled with mouse anti-FLAG clone M2 (Sigma) followed by
PE-labeled goat anti-mouse antibody (Dako). Cells transiently transfected
with the N-terminal receptors were stained with mouse anti-hemagglutinin A
clone 12CA5 (Abcam) followed by PE-labeled goat anti-mouse. Only recep-
tor-expressing cells were included in analyses (Figures S5 and S6). Cells
were cultured in Dulbecco’s modified Eagle’s medium (Lonza) supplied with
10% fetal calf serum (Invitrogen). For receptor expression determination on
neutrophils of different species, see Supplemental Experimental Procedures.
All in vitro experiments with cells were performed with RPMI (Invitrogen)
supplemented with 0.05% human serum albumin (HSA; Sanquin), with cell
concentrations adjusted to 5 3 106 cell/ml.
Design of Full-Length Receptor and N Terminus-Expressing
Plasmids
Full-length human C5aR, C5L2, C3aR, mouse (C57BL/6) C5aR, macaque
(Macaca fascicularis) C5aR, and rabbit (New Zealand white) C5aRwere cloned
into a pcDNA3.1 vector (Invitrogen) as described previously (Postma et al.,
2005). Briefly, the amplification reactions were performed on QUICK-Cloneost & Microbe 13, 584–594, May 15, 2013 ª2013 Elsevier Inc. 591
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Clontech) using PfuTurbo DNA polymerase (Stratagene). The C5aR of
macaque and rabbit, which reside on a single exon, were amplified using chro-
mosomal DNA isolated from blood. The following human C5aR/C3aR chi-
meras were constructed using overlap extension PCR: N-C3aR/TM-C5aR, in
which amino acids 1–37 from the C5aR were substituted for amino acids
1–23 from the C3aR, and N-C5aR/TM-C3aR, in which amino acids 38–350
from the C5aR were substituted for amino acids 24–482 from the C3aR
(Postma et al., 2005). To confirm surface expression of each described
GPCR, an N-terminal FLAG tag (DYKDDDDK) was placed after the first methi-
onine. An extramethionine was included directly after the FLAG tag to keep the
N-terminal sequence intact. N termini of the human C5aR (amino acid 1–38)
and C5L2 (amino acid 1–37), including a hemagglutinin A epitope tag, were
cloned into a pDISPLAY plasmid (Invitrogen) (Postma et al., 2005). Primer
designs, restriction sites, and accession numbers used in this study are
displayed in Table S2.
THP-1 Differentiation and C5aR Downregulation
THP-1 monocytic cells were grown in RPMI 1640 (Life Technologies) supple-
mented with 10% fetal calf serum (Lonza), 2 mM glutamine, and 50 mM b-mer-
captoethanol. THP-1 monocytes were differentiated into macrophages by the
addition of 100 ng/ml phorbol myristate acetate (PMA; InvivoGen) for 48 hr.
THP-1 monocytes were transduced with lentiviruses expressing human
GIPZ shRNAmir targeting c5aR1 (Thermo Fisher Scientific; shRNA1: clone
ID V3LHS_635740; shRNA2: clone ID V3LHS_635738; shRNA3: clone
IDV3LHS_635742) or targeting inflammasome adaptor asc (shRNA control)
(Perret et al., 2012). Then 48 hr posttransduction, transduced cells were
selected using puromycin (5 mg/ml) during a period of 4 days. Expression of
shRNA in PMA-differentiated macrophages was checked by flow cytometry
using GFP expression as a surrogate marker. To assess C5aR expression level
in PMA-differentiated macrophages, C5aR mRNA levels were checked by
quantitative RT-PCR with primers indicated in Table S2 using Improm (Prom-
ega) and LightCycler 480 SybrGreen I Master (Roche) kits on a LightCycler
480 II (Roche). C5aR expression level was normalized to GAPDH expression
level.
Monoclonal Antibody Binding Competition Assay
Neutrophils were incubated in a volume of 50 ml RPMI-HSA at 5 3 106 cell/ml
with 313 nM protein for 30 min on ice. After washing, different antibodies were
applied and incubated for 30 min on ice as described elsewhere (Bardoel
et al., 2012). PE-conjugated mouse anti-human antibodies were used to
detect the C5aR (clones: S5/1, BioLegend; P12/1, AbD Serotec; D53-1473,
BD Biosciences) and CXCR2 (clone 48311.211, R&D Systems). Fluorescence
was detected by flow cytometry and compared to cells incubated without
protein.
Binding Assays
Binding of the polyhistidine-tagged proteins to cells was tested using detec-
tion of the polyhistidine tag as described previously (Prat et al., 2009). After
incubation with the protein for 30 min in a total volume of 50 ml on ice, cells
(5 3 106 cell/ml) were washed and resuspended with a fluorescein isothiocy-
anate (FITC)-conjugated mouse anti-his antibody (Life Span Biosciences).
After 30 min incubation on ice, cells were washed and analyzed by flow cytom-
etry. Analysis of binding to transiently transfected HEK cells was limited to
receptor-positive cells. Half-maximal effective binding concentrations were
calculated using nonlinear regression analyses.
Cell Permeability Assays
Cells were exposed to recombinant proteins or 5% crude bacterial superna-
tant in a volume of 50–100 ml RPMI-HSA at 53 106 cell/ml with 2.5 mg/ml pro-
pidium iodide (PI) or DAPI. Cells were incubated for 30 min at 37C with 5%
CO2 and subsequently analyzed by flow cytometry. Pore formation was
defined as intracellular staining by PI or DAPI. For competition experiments,
cells were preincubated with C5a (Bachem) or CHIPS for 15 min at room tem-
perature before challenge with PVL. As PVL is a two-component toxin, equi-
molar concentrations of polyhistidine-tagged LukS-PV and LukF-PV were
used. Analysis of pore formation in transiently transfected HEK cells was
limited to receptor-positive cells. Half-maximal effective lytic concentrations592 Cell Host & Microbe 13, 584–594, May 15, 2013 ª2013 Elsevier Iwere calculated using nonlinear regression analyses. Detection of cell perme-
ability induced by supernatants of clinical S. aureus isolates is described in
Supplemental Experimental Procedures.
Quantification of Receptor Expression Levels
Freshly isolated human leukocytes or stably transfected cells were incubated
in a total volume of 50 ml at 5 3 106 cell/ml with immunoglobulin G (IgG) 2a-k
mouse anti-C5aR antibody clone S5/1 (AbD Serotec) or IgG2a-k mouse anti-
C5L2 clone 1D9-M12 (BioLegend), followed by FITC-conjugated goat-anti-
mouse antibody (Dako). Antibody binding was quantified by calibration to
defined antibody binding capacity units using QIFIKIT (Dako).
Neutrophil Priming for the Oxidative Burst
Human neutrophils were resuspended in IMDM with 25 mM HEPES (without
phenol red) supplemented with 0.1% HSA at a cell concentration of 1.25 3
106 cell/ml. Half of the cells were incubated for 5 min with 700 nM
CHIPS31–121 to block the C5aR. In a white 96-well microplate, 50 ml cells
were primed for 30 min at 37C with 10 ng/ml TNF-a (Sigma), 1 nM C5a
(Bachem), and PVL (1, 0.5, or 0.25 nM) or with buffer as control. Subse-
quently, 100 ml HBSS-0.1% HSA containing 337 mM luminol was added
and the chemiluminescence response recorded every 0.5 s for a total of
200 s. After 30 s of baseline recording, fMLP was injected (final concentration
1 mM) to stimulate the oxidative burst and recording continued as relative
light units in a luminometer (LB960 Centro; Berthold). For each sample, the
area under the curve (AUC) after addition of fMLP was calculated, setting
recordings in the first 30 s as baseline. To compare various experiments,
AUC values were expressed relative to buffer-treated cells stimulated with
fMLP. Cells without fMLP stimulation gave a continuous baseline recording
during the 200 s.
Peptide Synthesis, Isothermal Titration Calorimetry, and ELISA
To study the N-terminal part of the C5aR, peptides comprising of amino acids
7–28 (TTPDYGHYDDKDTLDLNTPVDK) were used, of which one was sulph-
ated at both tyrosines at positions 11 and 14. Sulphated and nonsulphated
C5aR peptides were synthesized on a 433A peptide synthesizer (Applied Bio-
systems) applying Fmoc/tBu chemistry according to amethod described else-
where (Bunschoten et al., 2009). The final peptides were checked for purity
(>98%) and composition by high-performance liquid chromatography and
mass spectrometry. Peptide concentrations were determined by weight.
Isothermal titration calorimetry with polyhistidine-tagged LukS-PV was per-
formed on an ITC200 microcalorimeter (MicroCal) (Ippel et al., 2009).
The data were analyzed using the MicroCal Origin software and fitted by
nonlinear regression analysis. Three independent experiments were carried
out. The experimental errors were estimated by Monte Carlo simulations.
For ELISA, a 96-well plate (Nunc MaxiSorp) was coated with 3.6 mM
sulphated or nonsulphated C5aR peptide. After blocking with 4% skimmed
milk, polyhistidine-tagged proteins were applied. After washing, mouse
monoclonal anti-his-tag antibody (Novagen) was added, followed by incuba-
tion with a horseradish-peroxidase-labeled goat anti-mouse IgG (1/10,000,
SouthernBiotech) for 1 hr at 37C. After washing, TMB was added as sub-
strate, the reaction was stopped with H2SO4, and optical density at 450 nm
was measured (Bardoel et al., 2012).
Calcium Mobilization Assays
Calcium mobilization in neutrophils and U937-C5aR cells was performed as
previously reported (Postma et al., 2005). Briefly, cells were loaded with 2 mM
Fluo-3AM in RPMI-HSA for 20 min at room temperature under constant
agitation, washed with buffer, and suspended to 5 3 106 cell/ml in RPMI-
HSA. Subsequently, the cells were preincubated with LukS-PV, LukF-PV,
or CHIPS for 5 min at room temperature. Each sample of cells was first
measured for approximately 10 s to determine the basal fluorescence level.
Next, concentrated C5a (Sigma, final concentration 1 nM) or C5a C-terminal
peptide (Bachem, Tyr65, Phe67 C5a 65–74: YSFKDMQLGR, final concentra-
tion 2.5 mM) was added and rapidly placed back in the sample holder to
continue the measurement. Cells were analyzed using a flow cytometry
gated on forward and side scatter to exclude dead cells and debris. The
relative increase in fluorescence was expressed in comparison to noninhi-
bited cells.nc.
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Graphical and Statistical Analyses
Flow cytometric analyses were performed with FlowJo (Tree Star Software).
Statistical analyses were performed with Prism (GraphPad Software). Statisti-
cal significance was calculated using ANOVA and Student’s t test.
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